Adamas Pharmaceuticals Incorporated (NASDAQ:ADMS) Can't Be Less Risky. Short Interest Decreased

Lloyd Doyle
January 12, 2018

Point72 Asset Management L.P. now owns 850,165 shares of the specialty pharmaceutical company's stock valued at $17,998,000 after acquiring an additional 735,165 shares in the last quarter. Piper Jaffray Companies restated an overweight rating and set a $30.00 price target on shares of Adamas Pharmaceuticals in a report on Friday, September 1st. Armistice Capital Llc who had been investing in Adamas Pharmaceuticals Inc (Call) for a number of months, seems to be less bullish one the $803.87M market cap company. About 516,657 shares traded.

Versartis, Inc. (NASDAQ:ADMS) scores higher than Adamas Pharmaceuticals, Inc. It has underperformed by 17.10% the S&P500.

Rr Advisors Llc decreased its stake in Western Gas Partners (WES) by 7.77% based on its latest 2017Q3 regulatory filing with the SEC. The company has market cap of $762.64 million. The stock increased 4.72% or $1.583 during the last trading session, reaching $35.143. About 417,427 shares traded. MPLX LP (NYSE:MPLX) has risen 11.48% since January 10, 2017 and is uptrending. It has outperformed by 36.58% the S&P500.

Sphera Funds Management Ltd, which manages about $700.90 million US Long portfolio, upped its stake in Ignyta Inc (NASDAQ:RXDX) by 59,300 shares to 459,300 shares, valued at $5.67 million in 2017Q3, according to the filing. It also reduced its holding in Sarepta Therapeutics Inc (NASDAQ:SRPT) by 16,700 shares in the quarter, leaving it with 46,520 shares, and cut its stake in Jpmorgan Chase & Co (NYSE:JPM).

Zacks Investment Research lowered shares of Adamas Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Friday, January 5th. Therefore 91% are positive. Adamas Pharmaceuticals had 26 analyst reports since August 7, 2015 according to SRatingsIntel. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the company. They issued an "outperform" rating for the company. Adamas Pharmaceuticals Inc has a 1-year low of $12.07 and a 1-year high of $19.50. Mizuho has "Buy" rating and $48.0 target. As per Friday, October 16, the company rating was downgraded by TheStreet.

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The stock has a consensus rating of "Buy" and a consensus target price of $28.43. As per Monday, October 10, the company rating was maintained by. Piper Jaffray maintained the shares of ADMS in report on Thursday, August 31 with "Buy" rating. The rating was initiated by Aegis Capital on Tuesday, September 22 with "Buy". 1 is equivalent to a buy rating, 3 a hold rating, and 5 a sell rating. Therefore 79% are positive.


ADMS has been the subject of several research reports. The company was maintained on Wednesday, November 8 by Noble Financial. Morgan Stanley initiated the stock with "Equal-Weight" rating in Thursday, February 25 report. (NASDAQ:ADMS)'s near-term growth potential. On Wednesday, September 6 the stock rating was maintained by Wedbush with "Buy". That puts the market capitalization at $807.63 mln. The firm earned "Hold" rating on Thursday, July 27 by Credit Suisse.

Since August 10, 2017, it had 0 insider buys, and 4 selling transactions for $680,004 activity. $11.33M worth of Mastercard Incorporated (NYSE:MA) shares were sold by Mastercard Foundation. Shares are trading price at $32.15 with move of -5.52%.

Investors sentiment decreased to 0.84 in Q3 2017. Its down 0.38, from 1.22 in 2017Q2. 29 funds opened positions while 85 raised stakes. Duff & Phelps Investment Mngmt invested in 1.83 million shares. Cv Starr Trust holds 3.18% or 196,200 shares. 483,668 are held by Metropolitan Life Insur New York. Following the transaction, the insider now directly owns 13,642 shares in the company, valued at approximately $232,459.68.

The stock of Diplomat Pharmacy, Inc. The firm has a market cap of $771.75, a P/E ratio of -10.08 and a beta of 1.13. The stock has relative volume of 0.49. Ftb Incorporated stated it has 0% in Aramark (NYSE:ARMK). They expect $-1.15 EPS, down 69.12% or $0.47 from last year's $-0.68 per share. Bancfirst Corp now has $1.71 billion valuation. EPS growth in next year is estimated to reach -6.40%.

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Other reports by Iphone Fresh

Discuss This Article

FOLLOW OUR NEWSPAPER